Is DICE Therapeutics, Inc. (DICE) a Buy, Sell, or Hold?
NASDAQ : DICE
DICE Therapeutics, Inc.
$47.55 USD
$0.03 (0.06%)
- Volume
- 4.33M
- Average Volume
- 1.91M
- Market Capitalization
- $2.27B
- P/E Ratio
- -22.97
- Dividend Yield
- 0.00%
- Price Target
- $60.00
- Year High
- $47.90
- Year Low
- $15.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $38.14
Company Overview
NASDAQ
J. Kevin Judice
Biotechnology
Healthcare
DICE
71
US
USD
Liquidity Metrics
-0.07
38.14
38.14
30.46
0.00
Sales & Valuation
-$
0.00
-9.99
-34.12
-1.69
Profitability
-$2.07
-$81.66M
0.00%
0.00%
56.07%
-13.75%
P/E Metrics
-22.97
-0.64
-0.64
Analyst Price Target & Rating
$60.00
$60.00
$60.00
0/5
10 Analysts
-20.75%
Financial Health Scores
42.92
3/9
$511.73M
$550.67M
$31.62M
-$110.31M
Key Metrics (TTM)
$1.82B
0.00
-21.96
38.14
56.07%
-14.80%
-4.36%
-2.93%
0 days
Company Executives
| Name | Title |
|---|---|
| J. Kevin Judice | Founder, Chief Executive Officer & Director |
| Scott Robertson | Chief Bus. & Financial Officer |
| Timothy Lu | Chief Medical Officer |
| John R. Jacobsen | Chief Scientific Officer |
| Venkat Thalladi | Senior Vice President of CMC |
| Mary Riley | Gen. Counsel |
| Paul Fatheree | Senior Vice President of Medicinal Chemistry |
Poll Results
No votes yet today — be the first to share your view!
About DICE Therapeutics, Inc. (NASDAQ:DICE) Stock
DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics. Their flagship therapeutic asset is DC-806, an orally administered antagonist designed to inhibit interleukin-17, a pivotal pro-inflammatory signaling molecule widely recognized as a validated target across numerous immunology indications. Furthermore, DICE is advancing other oral treatment options, including therapies aimed at the α4β7 integrin for the management of inflammatory bowel d ... iseases, and compounds targeting the αVβ1/αVβ6 integrin to treat idiopathic pulmonary fibrosis. Beyond these areas, the company also dedicates efforts to immuno-oncology, specifically developing antibody-based therapeutics. Established in 2013, DICE Therapeutics is headquartered in South San Francisco, California.
Frequently Asked Questions
-
What is the current DICE Therapeutics, Inc. (DICE) stock price?
-
DICE Therapeutics, Inc.(NASDAQ:DICE) stock price is $47.55 in the last trading session. During the trading session, DICE stock reached the peak price of $47.9 while $15.08 was the lowest point it dropped to. The percentage change in DICE stock occurred in the recent session was 0.06% while the dollar amount for the price change in DICE stock was $0.03.
-
DICE's industry and sector of operation?
-
The NASDAQ listed DICE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DICE?
-
J. Kevin Judice | Founder, Chief Executive Officer & Director
Scott Robertson | Chief Bus. & Financial Officer
Timothy Lu | Chief Medical Officer
John R. Jacobsen | Chief Scientific Officer
Venkat Thalladi | Senior Vice President of CMC -
How many employees does DICE have?
-
Number of DICE employees currently stands at 71. DICE operates from 279 East Grand Avenue, South San Francisco, CA 94080, US.
-
Link for DICE official website?
-
Official Website of DICE is: https://www.dicemolecules.com
-
How do I contact DICE?
-
DICE could be contacted at phone #650 566 1402 and can also be accessed through its website. DICE operates from 279 East Grand Avenue, South San Francisco, CA 94080, US.
-
How many shares of DICE are traded daily?
-
The average number of DICE shares traded daily for last 3 months was 1.91M.
-
What is the market cap of DICE currently?
-
The market value of DICE currently stands at $2.27B with its latest stock price at $47.55